To date, many brain conditions are poorly medicated due to limitations in drug-delivery prevent treating patients efficiently. The prominent reason is the Blood Brain Barrier (BBB), which prevents most therapeutic molecules from reaching the brain – and severely limits the arsenal of brain therapeutics. NucleoTech is developing carriers that deliver a variety of drug-classes across the BBB, including biologics and RNA drugs. The company utilizes the BBBs own transfer mechanisms to allow therapeutic molecules through, by using nanobodies (also called Single Domain Antibodies) as carrier molecules that shuttle therapeutics into the brain by the process of Receptor-Mediated Transcytosis.